Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity

Christian Vaisse,1,2,3 Karine Clement,1,2 Emmanuelle Durand,2 Serge Hercberg,4 Bernard Guy-Grand,2 and Philippe Froguel1,2

1Centre National de la Recherche Scientifique, UPR A 8090, Institute of Biology of Lille, Lille, France
2Laboratoire de Nutrition et Service de Médecine et Nutrition, Hôtel-Dieu, Paris, France
3Department of Medicine and Diabetes Research Center, University of California San Francisco, San Francisco, California, USA
4Conservatoire National des Arts et Metiers, Paris, France

Address correspondence to: Christian Vaisse, University of California San Francisco, Department of Medicine and Diabetes Research Center, Room HSW1113, 513 Parnassus Avenue, San Francisco, California 94143-0573, USA. Phone: (415) 514-0530; Fax: (415) 476-1660; E-mail: vaisse@medicine.ucsf.edu.

Received for publication December 22, 1999, and accepted in revised form June 7, 2000.

By integrating an agonist satiety signal, provided by alpha–melanocyte-stimulating hormone (α-MSH), and an antagonist signal, provided by agouti-related protein (AGRP), the melanocortin-4 receptor (MC4-R) is a key element in the hypothalamic control of food intake. Inactivation of the gene encoding this G protein–coupled receptor causes obesity in mice. In humans, frameshift mutations in MC4-R cause an early-onset dominant form of obesity in two families. In this study we find a high frequency (4%) of rare heterozygous MC4-R mutations in a large population of morbidly obese patients. No such mutations were found in controls. By analyzing the phenotypes of the probands carrying these mutations, we demonstrate that these patients display a common, nonsyndromic form of obesity. Interestingly, functional analysis of the mutant receptors indicates that obesity-associated defects in MC4-R range from loss of function to constitutive activation. Transmission of these mutations in the families of the carriers indicates a variable expressivity that is not related to the functional severity of the mutations. This variable expressivity of MC4-R–associated obesity is not due to variations in genes for a-MSH or AGRP. Taken together, these results demonstrate that MC4-R mutations are a frequent but heterogeneous genetic cause of morbid obesity.


Introduction

Obesity is the most common and rapidly growing nutritional problem in Westernized countries. By dramatically raising mortality (1) and the risk of morbidity from hypertension, dyslipidemia, diabetes mellitus, and cardiovascular diseases (2), this condition has become one of the major public health concerns for the 21st century (3, 4). Obesity is a complex multifactorial disease caused by the interaction of genetic and environmental factors (5, 6). The potential implication of genetic factors in the development of human obesity is well demonstrated by the description of five monogenic forms of human obesity (7–15). The genes implicated in these forms of obesity encode proteins of the leptin axis and brain-expressed targets of leptin involved in the melanocortin pathway. They include leptin (7, 8), the leptin receptor (9), proconvertase 1 (11), pro-opiomelanocortin (POMC) (10), and the melanocortin-4 receptor (MC4-R) (12–14, 15). Except for MC4-R, mutations in these genes cause rare, recessive, syndromic forms of obesity, associated with multiple endocrine abnormalities (7, 10, 11, 13–15).

MC4-R is a 332-amino acid protein encoded by a single exon gene localized on chromosome 18q22 (16, 17). MC4-R belongs to the family of seven transmembrane G protein–coupled receptors (GPCR) and signals through activation of adenylate cyclase (16). MC4-R integrates an agonist signal provided by alpha–melanocyte-stimulating hormone (α-MSH) (18), a melanocortin produced by proconvertase 1–dependent cleavage of POMC (19) and an antagonist signal provided by agouti-related protein (AGRP) expressed in the hypothalamic arcuate nucleus, in neurons distinct from the POMC neurons (20, 21). The importance of MC4-R in body-weight regulation is clearly demonstrated by the obese phenotype of the homozygous MC4-R–deficient mice (22). Heterozygous MC4-R+/– mice present an intermediate average increase in weight, females being more severely affected than males (22).

We have reported a case of human obesity associated with a frameshift mutation in MC4-R (12). This case differed from the previously described monogenic forms of obesity by a dominant transmission of the morbidly obese phenotype and by the absence of associated endocrine symptoms (12). The description of a similar case (13) and the report of several MC4-R missense and nonsense mutations in 1% of two cohorts of extremely obese children (14) and adults (15) suggest that such mutations could be a more frequent cause of obesity than the syndromic forms due to the other
genes. Limited information on the function of most of the missense mutations as well as incomplete phenotypic characterization of the patients and their families have not yet allowed a case to be built for the overall importance of MC4-R mutations in human obesity.

Methods

Subjects and phenotypes. We randomly selected 209 subjects from a cohort of morbidly obese unrelated probands of independent families. DNA and clinical and metabolic data from these probands and their families were collected as described (23). Briefly, they were recruited through the Department of Nutrition at the Hôtel-Dieu Hospital in Paris or through a toll-free number in France. In their weight history, all these subjects had reached the diagnostic cut-off point for morbid obesity, i.e., body mass index (BMI) > 40 kg/m². Obesity was assessed by BMI, Z-scores (standard deviation over mean BMI at a given age and sex for a French reference population), retrospective weight history, and leptin levels. Metabolic complications of obesity were evaluated by carbohydrate, insulin, and lipid measurements. For some of the subjects we measured body composition by biphononic absorptiometry (DXA; Hologic Inc., Waltham, Massachusetts, USA) and resting metabolic rate by indirect calorimetry (Deltatrac II MBM200; Datex-Ohmeda, Trappes, France). Blood sampling was also performed after an overnight fast for hormone measurements. The clinical data of the 209 morbidly obese subjects were as follows: sex M/F = 120/89, age 42 ± 12.0 range [12–69], BMI = 51 ± 7.5. Obese morbidly obese subjects were as follows: sex M/F = 120/89, age 42 ± 12.0 range [12–69], BMI = 51 ± 7.5.

In both control groups, none of the subjects had reached the diagnostic cut-off point for obesity (BMI > 30) (see Table 2 for subject characteristics). In control group 2, 7.5% of subjects were overweight (BMI, 27–30). Informed consent was obtained from all subjects and the protocols were approved by the Ethics Committee of Paris (Hôtel-Dieu and Cochin). Genomic DNA was extracted from peripheral leukocytes for all subjects.

PCR–single-stranded conformational polymorphism analysis. The coding portion of the MC4-R gene was amplified using five primer pairs. The α-MSH–encoding sequence of the POMC gene and each exon of hAGRP were amplified with one primer pair. PCR reactions were performed in a 25-μL volume containing 1× GeneAmp PCR Buffer II using AmpliTaq DNA Polymerase in the presence of [α-32P]dCTP. Primer pairs forward (5¢–3¢) and reverse (5¢–3¢), length of the PCR products, annealing temperatures, and MgCl2 concentration in the PCR reaction are indicated as follows: MCAF (ATCAATTCAAGGGGACACG); MCAR (GATGGTGAATGCAGATTCT), MCBF (GTTAATTGTCGAAATGCAC)/MCBR (TTCACTGCAATTGAAACG); MCCF (TGAGTCTCTCTGGTTGAC)/MCCR (GGCTCATCAGAAACATGTTGA), MCDF (ACCATGTTCTCCATCGTCT)/MCDR (GAGACATGAAACCAGACACAA), MCEF (CCATTCTCTCCTCCACTTAAT)/MCEF (TGCAATGTTCTATTTGCATG), 55°C, 1.5 mM; POMCF (GAAGACTGGGCGCCGGCTGCT)/POMCR (CGTGCTCATGGCAGGGGCCTCG), 65°C, 1.5 mM (10% DMSO); ARTAF (TCTTCTCTGCTGACCCAG)/ARTAR (GTCACACCCTTGCTCATACT), 65°C, 0.5 mM (2.5% formamide); ARTBF (CGTTCCTCATCCATCTCG)/ARTBR (CCTACCCCTTTCTCCCTGGAC), 65°C, 0.5 mM; ARTCF (GTCGCGTTCCCAACCCCTCG)/ARTCR (CCTAATCTAGCCCCAGCACCT), 65°C, 1 mM (2.5% formamide). The radiolabeled PCR products were diluted 1:5 in formamide buffer, and electrophoresed on glycerol-free and 10% (vol/vol) glycerol-containing nondenaturing 5% polyacrylamide gels at room temperature or 4°C, respectively. The gels were electrophoresed at 60-20 W for 4–7 hours, dried, and autoradiographed overnight.

Cloning and sequencing. Sequence of the variant was first determined by reamplification of the PCR product and direct sequencing on an ABI 377. The variant and wild-type genes were amplified from genomic DNA using primers MC4AF and MC4ER and cloned into the pcDNA3/MC4-R/V5/His/Topo expression vector (Invitrogen, Carlsbad, California, USA).

PCR-RFLP analysis. For each variant found to result in a frameshift or missense mutation, a PCR-RFLP assay was designed. Single-stranded conformational polymorphism (SSCP) primers were used for amplification when the mutation was found to introduce or delete a restriction site for a commercially available restriction

254 The Journal of Clinical Investigation | July 2000 | Volume 106 | Number 2
enzyme. For the other mutations, primers with a sequence mismatch in the 3’ region were designed in order to create artificial mutation conditional restriction sites. The primer used, as well as the PCR conditions, are indicated next, followed by the restriction enzyme used, with mismatched bases underlined: mutation Thr11Ser, MCAF/MCAR, cut CaClI (only mutant cuts); mutation Arg18Cys, MCAF/MCAR, cut AcI (only wild-type [WT] cuts); mutation 47-48insG, (GCAAGCTGCCCAGATACAAG/MCCR, cut TTG) (only WT cuts); mutation Val103Ile, MCBF/MC4RB (TTGCAGTGGACAGGTACG/MCAR, cut MwoI [only WT] cuts); mutation Thr150Ile, MC4RC0 (TTGCAGTGGACAGGTACG/MCCR, cut MaelII (only WT cuts)); mutation Arg11Trp, MCFM/MCCR, cut CTG) (only mutant cuts); mutation Arg165Trp, MCCF/MCCR, cut MwoI (only mutant cuts); mutation Ile251Leu, MC4RD0 (GCGATTACCTTGACCAG/MCFD/MC4RDy, cut DdeI (only mutant cuts). The melanocortin receptor activity and binding assay in stably transfected cells. Stable cell lines were established by transfecting HEK 293 cells using Effectene (Qiagen, Hilden, Germany) and selected in 1 mg/mL Geneticin (Life Technologies, Merelbeke, Germany) with the cloned sequence confirmed and wild-type and mutant MC4-R. To avoid clonal variations, pools of stable transfomers were used in the assay. Equivalent expression of receptor by the different pools of stably transformed cells was assessed by Northern blot. The melanocortin receptor activation assay was adapted from Liu et al. (27) using pCRE/luciferase (pCRE-luc) (28), a cAMP-inducible luciferase-expressing plasmid. Stable cell lines expressing the wild-type or the different mutant receptors were transfected with pCRE-luc and either of two different constructs expressing wild-type or mutant MC4-R in a 6-well plate using Effectene. After 24 hours, cells from one well were split into 8 wells from a 48-well plate. At 48 hours after transfection, luciferase and binding assays were performed as described above for the stably transfected cells.

Transient-expression assays. For the transient luciferase-expression assays, HEK293 cells were cotransfected with pCRE-luc and either of the different constructs expressing wild-type or mutant MC4-R and MC4-R activity and binding assay in stably transfected cells. Stably transfected cells, where wild-type and mutant MC4-R were expressed, were plated in 48-well plates the day before the binding experiment was performed. Cells were washed with 200 µL of binding medium (1 mg/mL BSA in Ca2+/Mg2+ PBS) and incubated in 150-µL binding medium containing 40,000–60,000 cpm of [125I] NDP-MSH (NEN, Billerica, Massachusetts, USA) per well. Series concentration of unlabeled α-MSH were used to compete with the labeled NDP-MSH. Controls for nonspecific binding contained 10 µM unlabeled α-MSH. After 1 hour of incubation, the binding medium was aspirated, cells were washed with 400 µL of binding medium, and 200 µL of 0.1 N NaOH was added. Membrane-bound counts per minute were determined in a Cobra gamma counter (Packard, Downers Grove, Illinois, USA). Total specific binding and IC50 values were determined by nonlinear regression analysis from triplicate data points using Prism software (GraphPad Software for Science, San Diego, California, USA).

Genetic and phenotypic analysis of family 1417. The Genebridge 4 radiation panel (Research Genetics, Huntsville, Alabama, USA) was screened with primer pairs MC4CF/MC4CR and MC4DF/MC4ER using the same conditions as for the PCR-SSCP. Out of 93 clones, 29 were positive, 61 were negative, and 3 were inconsistent. Data were submitted to World Wide Web to http://www-genome.wi.mit.edu/egbin/contig/rhmapper.pl, at the Whitehead Institute (Cambridge, Massachusetts, USA) for computational and statistical analysis. MC4-R was mapped on the chromosome 18 framework map at 0cR300 from the STS WI-4461 (lod > 3). WI-4461 had been unambiguously assigned to YAC 938’1 (Whitehead Institute). Physical mapping of MC4-R to this YAC (Fondation Jean Dausset, Paris, France) was confirmed by PCR. Since the microsatellite marker D18S474 and D18S68, from the PE ABI panel (PE Biosystems, Foster City, California, USA) to genotype family 1417 at the MC4-R locus as described (29). For fluorescence in situ hybridization (FISH) analysis of the MC4-R locus on the proband, purified YAC 938’1 was labeled with biotin by nick translation (Boehringer Mannheim, Mannheim, Germany), following the manufacturer’s instructions, and used as a probe. The FISH
assay was carried out as described (30). Briefly, 100 ng of biotin-labeled DNA probe was hybridized to chromosomal and signals detected with FITC-conjugated avidin. Forty metaphases were analyzed. Southern blot analysis of MC4-R was performed as described (31). Genomic DNA from the proband and from one control individual was digested with the restriction enzymes EcoRI, PstI, BstNI, and BanII. The probe encompassed 600 bp of the 5’ untranslated region of the human MC4-R gene.

Results

Frequency of MC4-R mutations and association with human morbid obesity. Two hundred nine morbidly obese patients (BMI > 40 kg/m²) were screened for mutations in the MC4-R gene by PCR-SSCP under conditions reported to be more than 90% sensitive for detecting single-base substitutions (32). Reamplification and direct sequencing determined the sequence of each detected variant. We found 11 different variants, encoding nine missense mutations (data not shown). The other mutations were not detected in the control 1 group.

To evaluate the significance of the high frequency of rare missense mutations in the obese cohort we screened for mutations in the MC4-R coding sequence of these individuals (33). Two missense mutations described previously, Arg165Trp, Ile170Val, and Ile301Thr were found at a similar frequency both in this control group and in the obese populations. No association of these polymorphisms with any obesity-related phenotype was observed in either group [data not shown]. The other mutations were not detected in the control 1 group.

To assess the frequency of the missense and frameshift mutations in 254 nonobese controls (control 1 group). Two missense mutations described previously (14, 33), Val103Ile and Ile251Leu, were found at a similar frequency both in this control group and in the obese populations. No association of these polymorphisms with any obesity-related phenotype was observed in either group [data not shown]. The other mutations were not detected in the control 1 group.

In this assay, both the wild-type MC4-R and the MC4-R containing the polymorphic amino acid change Ile251Leu exhibited a similar dose-response pattern curve (Figure 1a). A similar result, confirming data published previously (15), was found for the other polymorphic change, Val103Ile (not shown).

Mutations Thr150Ile, Arg165Trp, Ile170Val, and Ile301Thr all led to a reduction in receptor activation in our assay (Figure 1b). This result could be due to reduced expression of these mutated receptors at the cell membrane, reduced affinity for the ligand, or defective integral membrane function of the mutated receptor. To further explore the defects caused by these mutants we evaluated the affinity for ligand of cells expressing these mutated receptors in a binding assay. In the presence of subsaturating amounts (200 pM) of [125I]NDP-α-MSH, specific binding to the stably transfected (not shown) and transiently transfected cells expressing the mutants Arg165Trp, Ile170Val, or Ile301Thr were reduced by over 80%, as compared with wild-type cells indicative of a strong reduction in cell-surface expression and/or ligand affinity of these mutated receptors (Figure 1e). Mutation Thr150Ile led to an intermediate reduction in receptor binding (Figure 1e), both in transiently and stably transfected cells. In a competition-binding assay this mutation caused an increase in the IC₅₀ for α-MSH, as compared with the wild-type receptor (Figure 1f).

Mutation Leu250Gln displayed an unexpected pattern of activation. This receptor showed a major increase in basal activity (Figure 1c) and full activation by α-MSH. This result was confirmed by comparing the activity of this mutant to the activity of the wild-type MC4-R under basal conditions in a transient assay (data not shown). This receptor has a 10-fold higher affinity for α-MSH, as determined in a competition-binding assay (Figure 1f).

Mutations Arg18Cys and Thr11Ser, both changing amino acids in the extracellular NH₂-terminal portion of MC4-R, did not have a major impact on the activity of the receptor in our cAMP-dependent luciferase assay (Figure 1d) nor on the affinity for α-MSH (data not shown). This receptor has a 10-fold higher affinity for α-MSH, as determined in a competition-binding assay (Figure 1f).

Clinical characteristics of morbidly obese patients carrying MC4-R mutations. To search for specific phenotypes in the newly discovered MC4-R mutation carriers, we compared the clinical and biological characteristics of these patients with those of the other morbidly obese subjects screened for mutation as controls (Table 2). Mean BMI, maximal BMI reached during adult life, and minimal BMI reached after periods of caloric restriction were similar between both mutated and nonmutated groups (P = 0.6 and P = 0.5, respectively). In contrast, retrospective weight history indicates that the obese carriers of MC4-R mutations have an increased tendency to childhood obesity as compared with the other screened subjects (67 vs. 45.5%, P = 0.07, respectively) and had a higher standard deviation of BMI at age 20 (Z-score at 20 years: 3.5 ± 3.5 vs.
1.4 ± 2.3, P = 0.04). The food intake assessed by dietary history was similar between groups as were the restraint, disinhibition, and hunger factors, suggesting no quantitative or qualitative modification of food intake behavior due to MC4-R mutation. The proportions of type 2 diabetic (27.0 vs. 25.0%) or glucose-intolerant subjects (16 vs. 12.5%) were not statistically different between both nonmutated and mutated obese groups (P = 0.6). As indicated by homeostatic model assessment of fasting glucose and insulin (23), nondiabetic obese subjects were markedly insulin resistant when compared with control group 1, but no difference was seen between MC4-R mutation bearers and nonbearers (data not shown). Fasting insulin and triglyceridemia were raised in both obese groups compared with the control (P < 0.05), but were similar between obese groups. In addition, no difference was seen for the sex-adjusted mean leptin in both groups (P = 0.7). Hormone measurements were performed in three individuals with MC4-R mutations. The corticotropin axis and thyrotropin axis of the proband carrying the 47–48insG mutation were normal (0800 hours: 163 ng/mL [110 to 250], 1600 hours: 75 ng/mL [20 to 90], after dectancyl < 10 ng/mL; T4 = 7.6 pg/mL, TSH = 3.6 mUI/mL). Similarly, the probands carrying the Leu250Gln and the Arg165Thr mutations had normal cortisol and thyroid hormone levels.

Variable penetrance and expressivity of human MC4-R mutations. We evaluated the penetrance and expressivity of the rare MC4-R mutations in all available family members of the probands. A total of 29 family members were screened for mutation using the mutation-specific PCR-RFLP assays designed for the association studies. Carriers of MC4-R mutations were found in nine subjects from four families (Figure 2). In the families 1143 (Figure 2a), 1261 (Figure 2b), and 1283 (Figure 2c), segregating mutations Arg165Thr, Ile170Val, and Ile301Thr, respectively, all the mutation carriers had a history of obesity, but the age of onset and the severity of obesity varied between and within these families. In sharp contrast, the three MC4-R–mutation carriers in family 1417 had no history of obesity (Figure 2e). The MC4-R mutation segregating in this family is the new MC4-R 47-48insG frameshift mutation. This mutation results in the expression of an aberrant peptide containing the first 16 amino acids of MC4-R and 12 additional amino acids. True haploinsufficiency therefore should be expected in the carriers of this mutation. Careful clinical assessment of the nonobese heterozygous MC4-R 47-48insG carriers of family 1417 did not show any findings that explain the incomplete penetrance of obesity in these individuals (Figure 2e).

The hypothesis of a recessive transmission of obesity linked to MC4-R was evaluated in family 1417. Genotyping at the MC4-R locus indicated that the proband shared the same haplotypes as her younger lean brother. FISH analysis did not show any chromosomal rearrangement of the MC4-R locus in the proband.

Southern blots using multiple restriction enzymes did not show evidence for a deletion at the MC4-R locus. Sequence of the entire MC4-R gene, including the 5’ and 3’ untranslated regions, did not show a second MC4-R mutation in the proband.

Variable penetrance of obesity associated with MC4-R mutations in family 1417, as well as variable expressivity of obesity associated with MC4-R mutations in other families, could be due to genetic variations in the MC4-R ligand genes. One hundred morbidly obese patients from the same cohort as that screened for MC4-R mutations were screened for mutation by PCR-SSCP in the three exons encoding the AGRP gene and in the α-MSH–encoding portion of the POMC gene. No variants were found in the α-MSH–encoding portion of the POMC gene in all the tested subjects. Two silent mutations (G423A and C690T) were found in the AGPR-encoding sequence of two different patients.

Discussion
Polycystic metabolic diseases, such as obesity, have been suggested to result from the additive and interactive effects of a limited number of common genetic variants (5). Alternatively, the predisposition to excessive weight gain in a given environment could depend upon multiple rare mutations (with different penetrance) in a large set of genes (5). This study provides evidence that MC4-R is the first of such genes. MC4-R shows a higher mutation frequency in common morbid obesity than in normal-weight control individuals. This significant trend is observed across studies. Including ours, five groups have independently screened the MC4-R for mutations in a total of 1,136 patients (12–15, 33); 771 were extremely obese (weight > 99th percentile in children or BMI > 40 kg/m2 in adults), and 315 had a BMI below 30 (50 had unknown or intermediate BMI). Three missense variants, Val103Ile, Thr112Met, and Ile251Leu, and one silent mutation were found both in extremely obese and lean individuals. In contrast, whereas a total of 15 mutated MC4-R alleles have been

<table>
<thead>
<tr>
<th>Base change</th>
<th>Effect on amino acid sequence</th>
<th>Morbidly obese (n = 209)</th>
<th>Control 1 (n = 254)</th>
<th>Control 2 (n = 112)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A-307-G</td>
<td>Val103Ile</td>
<td>8</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>A-751-C</td>
<td>Ile251Leu</td>
<td>3</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>C-593-T</td>
<td>Silent</td>
<td>1</td>
<td>ND</td>
<td>1</td>
</tr>
<tr>
<td>47-48insG</td>
<td>16 +12 amino-acids</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>A-31-G</td>
<td>Thr150ile</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>C-52-T</td>
<td>Arg18Cys</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>C-449-T</td>
<td>Thr150ile</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>A-508-G</td>
<td>Ile170Val</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>C-493-T</td>
<td>Arg165Thr</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>T-749-A</td>
<td>Leu250Gln</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>T-902-C</td>
<td>Ile301Thr</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

The morbidly obese and the control 2 populations were screened by PCR-SSCP. The control 1 population was screened by PCR-RFLP for every functionally relevant mutation detected in the morbidly obese population. ND, not determined.
found only in 18 extremely obese probands (2.3% of 771), no additional mutation has been found only in the 315 lean individuals (P < 0.005, Fisher exact test). The high frequency (4%) of rare MC4-R mutations found in our French morbidly obese population does not significantly differ from that of previously screened morbid obese populations, but confirms that MC4-R mutations are implicated in a large absolute number of cases of morbid obesity. Indeed, since 0.5% of the French population has a BMI above 40 kg/m² (34), our results suggest that the prevalence of morbid obesity due to MC4-R mutation in the French population could be close to 1 in 5,000.

Previously, rare monogenic forms of human obesity have been identified through associated endocrine abnormalities (7–11). In contrast, by extensively phenotyping and comparing MC4-R mutation carriers with non-mutation carriers, we did not detect any specific clinical or biological symptoms characterizing the MC4-R mutation bearers, except for a trend toward earlier onset and more severe obesity at age 20. In the subgroup of patients presenting with a sex-specific standard deviation of BMI above 1.5 at age 20, the frequency of rare mutations in MC4-R was 6%. Whereas this finding is consistent with the frequency of MC4-R mutations found in obese children selected with a lower cut-off point for obesity (14), additional studies in larger cohorts will be necessary to confirm the increased sensitivity brought by this diagnostic criteria.

Confirmation of the pathogenic role of missense mutations involves functional characterization of the mutant receptor. By systematically assaying the function of the different mutant receptors in a cell base system, we found that all but two of the obesity-associated missense mutations impaired the function of the receptor in our assay whereas polymorphic variants of the receptor did not. This result strengthens the epidemiological argument for a role of these MC4-R mutations in the obese phenotype of the probands and again underscores results obtained in previous studies. Indeed, the one nonsense (Tyr-35-Stop) (14) and the three frameshift mutations (732-733insGATT, 631-634delCTCT, 47-258...
insG) (refs. 12, 13, and this study) described in the MC4-R can be considered loss-of-function mutations. A previously studied mutation (Ile137Thr) has also been shown to impair the function of MC4-R (15). Together, 11 out of the 15 mutated MC4-R alleles found in 14 out of 18 extremely obese individuals have a significant impact on receptor function.

The two mutations (Thr11Ser and Arg18Cys) found in morbidly obese individuals that did not significantly modify the function of MC4-R are located in the NH2-terminal region of the protein. This NH2-terminal region of MC4-R can be deleted without affecting ligand binding (35). It is possible that this region is necessary for another property of the receptor that might

Figure 2
Pedigrees, mutation screening, and phenotypes in the available family members of MC4-R mutation carriers. For each mutation, the upper part of the figure represents the pedigree structure of the family of the carrier. Age (years), BMI (kg/m²), and Z-score (standard deviation of BMI) are indicated under each individual. Arrows indicate the probands. Hatched symbols denote obesity (30 ≤ BMI < 40 kg/m²). Filled symbols denote early-onset morbid obesity (BMI ≥ 40). Half-filled symbols denote a history of childhood obesity (obesity before age 20).

The lower portion of each part of the figure represents the result of PCR-RFLP genotyping of each available family member. Genotyping was performed using a specific assay for each mutation, as described in Methods. C+: positive control (amplified from the cloned mutation and digested); C–: negative control (amplified from the wild-type receptor and digested). (a) In family 1143 the Arg165Trp mutation was transmitted to the proband III:3 by her obese father II:1. He developed obesity during infancy (BMI = 31 kg/m² at 16 years, Z-score = 4.6 SDs of BMI). During adulthood, he reached the diagnostic cut-off point for morbid obesity, since his maximal lifetime BMI was 41 kg/m² at age 30. His lifetime weight variation was 90–125 kg. The proband’s cousin III:6, bearing the mutation, also had a morbid form of obesity of early onset (80 kg at age 10 years and 100 kg at age 16 years). Her mother, II:3, closely resembled proband III:3, but no precise phenotypic data were available. (b) In family 1261 the mutation Ile170Val was transmitted by the obese mother I:2, who developed obesity during puberty (at 14 years of age, BMI = 28 kg/m², Z-score = 3). Her adult lifetime weight variation was 50–90 kg. She also transmitted the mutation to her daughter II:3, who became overweight at puberty (at 14 years old, BMI = 28 kg/m², Z-score = 3.5), and her BMI was 30.4 kg/m² (Z-score = 3.8) at age 20. Her maximal weight was 82 kg after the age of 20. (c) In family 1283 all the carriers of mutation Ile301Thr were obese. The proband’s brother is a morbidly obese man (BMI 57.1, percent body fat 54%), with severe obesity developed early in infancy. His birth weight was normal (2.8 kg). He had a BMI of 22 kg/m² (Z-score = 4.3) at 9 years old, and he was morbidly obese (BMI = 47 kg/m², Z-score = 13) at 14 years. His adult lifetime weight variation was between 117 and 185 kg. His obesity is complicated by glucose intolerance and hypertriglyceridemia. The mutation was transmitted to this sibling pair by the father I:1, who had a less-severe form of obesity of later onset (after the age of 20 years). (d) In family 1413, no clinical nor genotype data were available for the parents of the proband II:2 carrying the constitutively active Leu250Gln mutation. Her brother II:1 is not carrying the mutation. (e) In family 1417 the 47-48insG frameshift mutation was transmitted to the proband II:3 by her nonobese mother I:2 (BMI = 21 kg/m²). She never had weight problems either during infancy or during puberty, and her maximal reached BMI was 22 kg/m². She moderately controls her body weight, with declared diet restriction below one per year, and is not a sportswoman. She also transmitted the mutation to her two older sons, II:1 and II:2. Both are nonobese young males, 25 and 24 years old, with a BMI of 25.5 and 22 kg/m², respectively.
Table 2

<table>
<thead>
<tr>
<th>Patient/mutation</th>
<th>Control 1</th>
<th>Control 2</th>
<th>Obese, no MC4-R mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n = 201</td>
<td>n = 254</td>
<td>n = 8</td>
</tr>
<tr>
<td>Age</td>
<td>42.0 ± 11.5 [12–69]</td>
<td>52.0 ± 7.0 [40–66]</td>
<td>57 ± 11 [33–87]</td>
</tr>
<tr>
<td>Sex (F/M)</td>
<td>152/49</td>
<td>168/86</td>
<td>65/47</td>
</tr>
<tr>
<td>Childhood overweight [%]</td>
<td>63 [32%]</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Puberty overweight [%]</td>
<td>123 [64%]</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Birth weight (kg)</td>
<td>3.5 ± 0.70 [1.5–5.5]</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Actual weight (kg)</td>
<td>140.0 ± 26.0</td>
<td>141.5</td>
<td>111</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>165.3 ± 9.2 [148–190]</td>
<td>164.4</td>
<td>156</td>
</tr>
<tr>
<td>BMI 20 y (kg/m²)</td>
<td>20 ± 2.0 [15–29]</td>
<td>-</td>
<td>29.0 ± 7 [17.5–50]</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>21.0 ± 1.8 [15–25]</td>
<td>23.0 ± 2.7 [18–29]</td>
<td>51.5 ± 7.5 [32–74]</td>
</tr>
<tr>
<td>% body fat</td>
<td>54 ± 7.7 [37–66.0]</td>
<td>-</td>
<td>53.0 ± 6.5 [19–50]</td>
</tr>
<tr>
<td>RMR (kcal per day)</td>
<td>1800</td>
<td>-</td>
<td>2488</td>
</tr>
<tr>
<td>Min BMI (kg/m²)</td>
<td>19 ± 1.8 [14–26]</td>
<td>-</td>
<td>28.0 ± 6.5 [19–50]</td>
</tr>
<tr>
<td>Max BMI [kg/m²]</td>
<td>23 ± 2.2 [16–29.7]</td>
<td>-</td>
<td>54.0 ± 8.5 [40–99.0]</td>
</tr>
<tr>
<td>% body fat</td>
<td>56.3 ± 6.5 [22.5–55]</td>
<td>-</td>
<td>64.5 ± 6.0 [32–74]</td>
</tr>
<tr>
<td>Total kcal intake</td>
<td>2023 ± 551 [716–4000]</td>
<td>-</td>
<td>2393 ± 900 [800–5000]</td>
</tr>
<tr>
<td>% lipids</td>
<td>38.4 ± 5 [19–60]</td>
<td>-</td>
<td>40.5 ± 9.0 [22.5–55]</td>
</tr>
<tr>
<td>Restriction</td>
<td>8.5 ± 4.2 [1–19]</td>
<td>-</td>
<td>6.0 ± 3.0 [1–19]</td>
</tr>
<tr>
<td>Disinhibition</td>
<td>8.4 ± 3.2 [2–16]</td>
<td>-</td>
<td>8.1 ± 3.7 [2–16]</td>
</tr>
<tr>
<td>WI</td>
<td>2 ± 1.2 [0.3–4.6]</td>
<td>-</td>
<td>1.8 ± 1.3 [0.3–4.6]</td>
</tr>
<tr>
<td>SI</td>
<td>2.02 ± 0.6 [1–4.5]</td>
<td>-</td>
<td>2.0 ± 0.7 [1–4.5]</td>
</tr>
<tr>
<td>LI</td>
<td>1.9 ± 0.6 [0.7–2.7]</td>
<td>-</td>
<td>2.2 ± 0.6 [0.7–2.7]</td>
</tr>
<tr>
<td>Glycemia (mM)</td>
<td>5.5 ± 1.07 [3.8–6.1]</td>
<td>-</td>
<td>6.9 ± 2.5 [3.8–19.0]</td>
</tr>
<tr>
<td>Insulinemia (m UI/mL)</td>
<td>10.0 ± 5.0 [4–54]</td>
<td>-</td>
<td>20.0 ± 15.0 [0.5–119.6]</td>
</tr>
<tr>
<td>Total-cholesterol (mM)</td>
<td>5.86 ± 0.96 [4–9]</td>
<td>-</td>
<td>5.0 ± 1.04 [2.7–5.7]</td>
</tr>
<tr>
<td>Total-TG (mM)</td>
<td>0.91 ± 0.5 [0.36–4.3]</td>
<td>-</td>
<td>1.7 ± 1.03 [0.4–8]</td>
</tr>
</tbody>
</table>

Phenotypes were assessed as described in Methods. Data are presented as mean ± SD [Range]. Data for the proband carrier of the previously described mutation 732-733insGATT (12) are indicated for comparison. No statistical differences were observed between the obese bearers and the nonbearers of MC4-R mutations for obesity-related phenotypes. RMR was measured in four subjects with MC4-R mutations. Except for the carrier of mutation 47-48insG, whose RMR was 1,790 kcal per day, which represented –14% of the RMR calculated by the Harris and Benedict formula, these subjects had a resting metabolic rate corresponding to the theoretical values. The body composition, measured for 26 nonmutated subjects and four mutated subjects, was similar in both groups. NIDDM, non–insulin-dependent diabetes mellitus; Max BMI, maximal BMI reached after the age of 20; Min BMI, minimal BMI reached after periods of dietary restriction; RMR, resting metabolic rate; HTA, hypertension; TG, triglyceride. WI, SI, LI; Work Index, Sport Index, Leisure Index, respectively, as defined in the Baecke questionnaire (25).
not be evaluated through our assays. Additional studies will be required to dismiss any functional effects for mutations Thr11Ser and Arg18Cys.

The Leu250Gln mutation described in this study is the first obesity-associated mutation leading to constitutive activation of MC4-R. Association of this mutation with obesity is surprising since activation of MC4-R should result in an increased satiety signal. Indeed, the proposed use of long-acting agonist of the MC4-R in the treatment of obesity should be reconsidered in view of this result. However, since constitutive activation in a cell-based assay might not accurately represent the in vivo behavior of this mutated receptor, additional studies are clearly required to precisely understand the role of the Leu250Gln MC4-R mutation in the obese phenotype of our proband.

Reduced penetrance and variable expressivity have been seen in most diseases linked to mutations in GPCRs (36). In this study we demonstrate, we believe for the first time, that heterozygous-null MC4-R mutations in humans do not always lead to obesity. Heterozygous MC4-R+/– mice also display a broad variability in phenotype with an adult weight ranging from that of wild-type to that of homozygous MC4-R−/− mice (22). Since the trait under consideration is a quantitative and environmentally dependent trait, a better estimation of the penetrance of obesity in MC4-R mutation carriers will require the review of large well-phenotyped pedigrees across multiple additional studies.

The reduced penetrance and variable expressivity of obesity associated with MC4-R mutations could be influenced by variants in modifier genes that are both intrinsic and extrinsic to the melanocortin pathway. We found no evidence for functionally significant variation in α-MSH or AGRP, which are both intrinsic to the pathway, but these negative data should be interpreted with caution.

The reduced penetrance and variable expressivity of obesity observed between families in this study could also be linked to the differential functional effects of the receptor mutations. Since many of the previous mutations found in MC4-R were expected to result in a truncated protein, it had been hypothesized that the obesity in the MC4-R mutation carriers resulted from haploinsufficiency (13, 14). In contrast, a recent study on a small population of patients with deletions of chromosome 18q, some of them hemizygous at the MC4-R locus, supports the hypothesis that the involvement of MC4-R in obesity may reflect a dominant-negative effect (37). In our study, both the reduced penetrance of obesity in heterozygous carriers of the MC4-R 47-48insG frameshift mutation and the constitutive activation observed for one of the missense mutants suggest that obesity associated with MC4-R mutations should not always be solely attributed to haploinsufficiency at this locus.

In summary, our results confirm that mutations in MC4-R are the most frequent genetic cause of common obesity described to date. The heterogeneity of obesity linked to MC4-R mutations clearly implies that functional assessment of MC4-R mutations will eventually routinely be required to evaluate the risk of obesity in MC4-R mutation carriers. In a broader perspective, this study suggests that the comparison of the occurrence of rare functionally relevant mutations between patient and control populations might represent the best method for implicating candidate genes in the pathogenesis of a multifactorial polygenic trait such as common obesity.

Acknowledgments

This work was supported by the Direction de la Recherche Clinique/Assistance Publique-Hôpitaux de Paris, Programme Hospitalier de Recherche Clinique (AOM 96088), and a grant from Institut de Recherche Internationale Servier. Part of this work was supported by a Howard Hughes Medical Institute Research Resource Program grant (76296-549901) to University of California San Francisco School of Medicine. C. Vaisse was supported by l’Institut National de la Santé et de la Recherche Médicale. The Danone Institute is gratefully acknowledged for giving access to the Danone/Suvimax DNA bank. We thank Valerie Delannoy, Cytogenetics Laboratory of the Institute of Biology of Lille, Genevieve Bonhomme, and Annie Legal for their excellent technical help. We thank G. Barsh for critical reading and insightful comments on the manuscript.